Martin Stork

13PUBLICATIONS

61CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 19, 2026

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

|Jun 12, 2026

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Oct 11, 2024

Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Ludmila Muronova, Ondrej Soucek, David Zihala

|Aug 26, 2024

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Martin Stork, Eva Ondrouskova, Michaela Bohunova

|Aug 26, 2024

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Dominik Fric, Martin Stork, Ivanna Boichuk

|Dec 11, 2022

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Monika Vlachová, Jana Gregorová, Petra Vychytilová-Faltejsková

Pageof 3

Frequent Collaborators

Sabina Sevcikova

Jiri Minarik

Roman Hajek

Tomas Jelinek

Jakub Radocha

Ludek Pour

Viera Sandecká

Eva Ondrouskova

Lucie Rihova

Lenka Radová

Frequent Collaborators

Sabina Sevcikova

Jiri Minarik

Roman Hajek

Tomas Jelinek